ストックスクリーナーアプリを入手
4.63
2.89%
0.13
アフターアワーズ：
4.58
-0.05
-1.08%
Myriad Genetics Inc (MYGN) 最新ニュース
Myriad Genetics expands cancer detection test availability - Investing.com
Myriad Genetics expands cancer detection test availability By Investing.com - Investing.com Canada
Myriad Genetics director Daniel Skovronsky resigns from board - Investing.com
Myriad widens cancer test access as breast study bolsters its case - Stock Titan
Myriad Genetics director Daniel Skovronsky resigns from board By Investing.com - Investing.com Canada
Form 8K Myriad Genetics Inc For: 23 June By Investing.com - Investing.com Canada
Board member Skovronsky exits Myriad Genetics (NASDAQ: MYGN) - Stock Titan
Myriad Genetics StockAnalyst views and sector comparison on a quiet news day - AD HOC NEWS
Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Myriad Genetics Inc (MYGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Myriad Genetics Inc (MYGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Myriad Genetics Inc (MYGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Myriad Genetics Inc (MYGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Myriad Genetics Inc (MYGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Myriad Genetics Inc (MYGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Myriad Genetics Inc (MYGN) Institutional Confidence - TradingKey
Myriad Genetics (NASDAQ: MYGN) CEO adds 3,542 shares via employee stock purchase plan - Stock Titan
Executive at Myriad Genetics (MYGN) adds 5,000 shares via ESPP plan - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Insider Sell Alert: Rashmi Kumar Sells 15,000 Shares of Myriad G - GuruFocus
Myriad Genetics (MYGN) director sells 15,000 shares under 10b5-1 plan - Stock Titan
Should You Add Myriad Genetics Stock to Your Portfolio Right Now? - Yahoo! Finance Canada
[144] MYRIAD GENETICS INC SEC Filing - Stock Titan
Director at Myriad Genetics (MYGN) receives 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) director awarded 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) grants 59,701 RSUs to director Mark Davis - Stock Titan
[Form 4] MYRIAD GENETICS INC Insider Trading Activity - Stock Titan
Myriad Genetics (MYGN) director receives 59,701 restricted stock units in equity grant - Stock Titan
Myriad Genetics (NASDAQ: MYGN) director receives 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) grants 59,701 RSUs to board director Bisaro - Stock Titan
Myriad Genetics (NASDAQ: MYGN) director granted 59,701 restricted stock units in equity award - Stock Titan
Myriad Genetics (NASDAQ: MYGN) shareholders approve 2026 equity and purchase plans - Stock Titan
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Myriad Genetics Inc Annual Shareholders Meeting Transcript - GuruFocus
Dr. Crystal Nelson Explains How Genetic Testing Is Transforming Mental Health Medication Treatment on YourUpdateTV - The Manila Times
Myriad Genetics (MYGN) CTO Raj Jampa receives 251,889 restricted stock units - Stock Titan
Myriad Genetics (MYGN) CTO Raj Jampa files initial Form 3 insider report - Stock Titan
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026 - TradingView
Myriad Genetics names Raj Jampa as chief technology officer - Investing.com UK
Myriad Genetics Names Raj Jampa as New Chief Technology Officer - The Globe and Mail
Press Release: Myriad Genetics Names Raj Jampa as New Chief Technology Officer - Moomoo
Statistics Show that Patients Want More Personalized Mental Health Care - KOIN.com
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad Genetics, Inc. (MYGN) News, Articles, Events & Latest Updates - Stocktwits
Myriad Genetics Inc stock (US62855J1043): Prolaris AI launch lifts focus - AD HOC NEWS
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - The Globe and Mail
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock - Yahoo Finance
MYGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Myriad Genetics’ Precise MRD Assay Data Presented at ASCO 2026 Shows Potential for Assessing Treatment Response and Monitoring Recurrence in Cancer Patients - geneonline.com
Myriad Genetics Highlights Data Demonstrating Broad Clinical Utility of Precise Mrd Assay At 2026 Asco Annual Meeting - marketscreener.com
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting - The Manila Times
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans - Yahoo Finance
Myriad Genetics (MYGN) Unveils Innovative Prolaris + AI Test for Prostate Cancer - GuruFocus
Myriad Genetics launches Prolaris + AI prostate cancer test - Investing.com UK
Myriad Genetics launches Prolaris + AI prostate cancer test By Investing.com - Investing.com Nigeria
1.86%
0.64%
大文字化:
|
ボリューム (24 時間):